PRESS RELEASES
-
Acceleron Secures $30M Private Financing
+ VIEW FULL Press Release -
Acceleron Pharma to Present at Two Upcoming Investor Conferences
+ VIEW FULL Press Release -
Acceleron Initiates Phase 1 Study of ACE-536
+ VIEW FULL Press Release -
Acceleron Pharma to Present at Two September Investor Conferences
+ VIEW FULL Press Release -
Acceleron Pharma Announces Global Collaboration with Celgene Corporation on ACE-536 Program
+ VIEW FULL Press Release -
Celgene and Acceleron Initiate Phase 2/3 Study of ACE-011 (sotatercept) to Treat Chemotherapy-Induced Anemia in Patients with Lung Cancer
+ VIEW FULL Press Release -
Acceleron Pharma Presents Anabolic Bone Effects of ACE-661 at International Scientific Meeting
+ VIEW FULL Press Release -
Acceleron Presents Positive Results from Phase 1 Study of ACE-041 in Patients with Advanced Cancer
+ VIEW FULL Press Release -
Acceleron Pharma to Present at Two Upcoming Investor Conferences in April
+ VIEW FULL Press Release -
Acceleron Appoints Kevin F. McLaughlin as Senior Vice President and Chief Financial Officer
+ VIEW FULL Press Release -
Acceleron Announces Interim Findings from the ACE-041 Phase 1, First-in-Human Clinical Trial at 22nd EORTC-NCI-AACR Symposium
+ VIEW FULL Press Release -
Acceleron Announces Departure of Jasbir Seehra, Ph.D. Chief Scientific Officer
+ VIEW FULL Press Release -
Acceleron Awarded Grants from the Qualifying Therapeutic Discovery Project Program
+ VIEW FULL Press Release -
Acceleron Presents Preliminary ACE-031 Results from a Phase 1 Multiple Ascending Dose Study in Healthy Volunteers
+ VIEW FULL Press Release -
FierceBiotech Names Acceleron Pharma as One of the “Fierce 15” of 2010
+ VIEW FULL Press Release -
Acceleron Pharma Announces Joint Development and Commercialization Agreement with Shire on Novel Muscle Therapeutics for Orphan Diseases
+ VIEW FULL Press Release -
Acceleron Pharma Receives FDA Orphan Designation for ACE-031 for the Treatment of Duchenne Muscular Dystrophy
+ VIEW FULL Press Release -
Acceleron Pharma Receives FDA Fast Track Designation for ACE-031 for the Treatment of Duchenne Muscular Dystrophy
+ VIEW FULL Press Release -
Acceleron Pharma Initiates Phase 2 Clinical Trial with ACE-031 in Patients with Duchenne Muscular Dystrophy
+ VIEW FULL Press Release -
Acceleron and Collaborators Publish Two Papers on ACE-041, a Novel Angiogenesis Inhibitor
+ VIEW FULL Press Release -
Acceleron Recognized by The Wall Street Journal as One of the Top 50 Venture-Backed Companies in the United States
+ VIEW FULL Press Release -
Acceleron to Present at the Cowen and Company 30th Annual Health Care Conference
+ VIEW FULL Press Release -
Acceleron Pharma Announces Addition of Two Novel Programs to Development Pipeline at the 28th Annual JP Morgan Healthcare Conference
+ VIEW FULL Press Release -
Acceleron Pharma to Present at the 28th Annual J.P. Morgan Healthcare Conference
+ VIEW FULL Press Release -
Acceleron Pharma Expands Management Team with Two New Appointments
+ VIEW FULL Press Release -
Acceleron Pharma Presents Findings of ACE-536, a Novel Red Blood Cell-Forming Agent, at the 51st Annual Meeting of the American Society of Hematology
+ VIEW FULL Press Release -
Alkermes Licenses Technology Platform for Long-Acting Fusion Proteins from Acceleron Pharma
+ VIEW FULL Press Release -
Acceleron Pharma to Present Data on ACE-011 and ACE-536 at the 51st Annual Meeting of the American Society of Hematology
+ VIEW FULL Press Release -
Acceleron Pharma Initiates First-in-Human Study of ACE-041, a Novel Angiogenesis Inhibitor, in Patients with Advanced Cancer
+ VIEW FULL Press Release -
Acceleron to Present at the UBS Global Life Sciences Conference
+ VIEW FULL Press Release -
Acceleron Pharma’s ACE-031 Increases Lean Body Mass in Phase 1 Single Dose Clinical Trial
+ VIEW FULL Press Release -
Acceleron to Present at the BMO Capital Markets 9th Annual Focus on Healthcare Conference
+ VIEW FULL Press Release -
Acceleron and Celgene Initiate Phase 2 Study of ACE-011 to Treat Chemotherapy-Induced Anemia
+ VIEW FULL Press Release -
Acceleron to Present ACE-031 Preclinical Study Results as Treatment for Loss of Muscle Mass and Function
+ VIEW FULL Press Release -
Acceleron Pharma to Present at Two Upcoming Investor Conferences
+ VIEW FULL Press Release -
Acceleron Selected as One of Boston Business Journal’s 2009 Best Places to Work
+ VIEW FULL Press Release -
Acceleron Announces Expansion of Cambridge Facilities by Additional 25% During Formal Unveiling of New Corporate Headquarters & Manufacturing Facility
+ VIEW FULL Press Release -
Acceleron Pharma Presents Preclinical Study Results for ACE-041 at the AACR 100th Annual Meeting 2009
+ VIEW FULL Press Release -
Acceleron to Present at the BioCentury Future Leaders in the Biotech Industry Conference
+ VIEW FULL Press Release -
Acceleron to Present at the Cowen and Company 29th Annual Health Care Conference
+ VIEW FULL Press Release -
Acceleron Introduces Breakthrough Program for Treatment of Anemia at the 27th Annual JP Morgan Healthcare Conference
+ VIEW FULL Press Release -
Acceleron to Present at the 27th Annual JP Morgan Healthcare Conference
+ VIEW FULL Press Release -
ACE-011 Phase 1 Results Published in the Journal of Bone and Mineral Research
+ VIEW FULL Press Release -
Celgene Corporation and Acceleron Pharma to Present ACE-011 Data at the 50th Annual Meeting of the American Society of Hematology
+ VIEW FULL Press Release -
Acceleron to Present at the Oppenheimer 19th Annual Health Care Conference
+ VIEW FULL Press Release -
Acceleron to Present at the 7th Annual Biotechnology Industry Organization Investor Forum
+ VIEW FULL Press Release -
Acceleron Initiates Phase 1 Clinical Trial for ACE-031 to Treat Diseases Involving Muscle Loss
+ VIEW FULL Press Release -
Celgene Corporation and Acceleron Pharma Initiate Phase 2 Study of ACE-011
+ VIEW FULL Press Release -
Acceleron to Present at Third Annual JMP Securities Healthcare Focus Conference
+ VIEW FULL Press Release -
Acceleron Pharma Acknowledged for Positive Impact on Economic Development in Massachusetts
+ VIEW FULL Press Release -
Acceleron to Present at the UBS Global Life Sciences Conference
+ VIEW FULL Press Release -
Acceleron to Present at the Jefferies 2nd Annual Healthcare Conference
+ VIEW FULL Press Release -
Acceleron Doubles Laboratory and Manufacturing Space and Increases Headcount by 40%
+ VIEW FULL Press Release -
Acceleron to Present at the Needham & Company 7th Annual Biotechnology and Medical Technology Conference
+ VIEW FULL Press Release -
Acceleron to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference
+ VIEW FULL Press Release -
ACE-011 Preclinical Data Published in the Proceedings of the National Academy of Sciences
+ VIEW FULL Press Release -
Acceleron Pharma and Celgene Corporation Receive Hart-Scott-Rodino Clearance for ACE-011 Collaboration
+ VIEW FULL Press Release -
Acceleron to Present at the Cowen and Company 28th Annual Health Care Conference
+ VIEW FULL Press Release -
Acceleron Pharma Announces Global Collaboration with Celgene Corporation on ACE-011 Program for Cancer-Related Bone Loss
+ VIEW FULL Press Release -
Acceleron Pharma Receives Grant for ACE-011 from the Multiple Myeloma Research Foundation
+ VIEW FULL Press Release -
Acceleron Pharma to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
+ VIEW FULL Press Release -
Acceleron Pharma to Present at the Massachusetts Biotechnology Council’s 9th Annual MASS Opportunities Investment Conference
+ VIEW FULL Press Release -
Acceleron Pharma to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
+ VIEW FULL Press Release -
Acceleron Pharma Completes $31M Series C Financing
+ VIEW FULL Press Release -
Acceleron Pharma’s ACE-031 Increases Muscle Mass In a Preclinical Model of Glucocorticoid-induced Muscle Loss
+ VIEW FULL Press Release -
Acceleron Pharma Website Awarded “Pharmaceutical Industry Standard of Excellence” by the Web Marketing Association
+ VIEW FULL Press Release -
Acceleron Pharma to Present at the Natixis Bleichroeder Hidden Gems Conference
+ VIEW FULL Press Release -
Acceleron Pharma Appoints Niels Borgstein, M.D. as Vice President, Medical Research
+ VIEW FULL Press Release -
Acceleron Pharma’s ACE-011 Increases Bone Mineral Density and Bone Strength in Preclinical Studies in Non-Human Primates
+ VIEW FULL Press Release -
Acceleron Pharma to Present at the UBS 2007 Global Life Sciences Conference
+ VIEW FULL Press Release -
Acceleron Pharma Presents Positive Phase 1 Results Demonstrating ACE-011 Increases Markers of Bone Formation
+ VIEW FULL Press Release -
Acceleron Pharma Appoints John L. Knopf, Ph.D., as Chief Executive Officer
+ VIEW FULL Press Release -
Acceleron Pharma to Present ACE-011 Bone Growth Data at the ASBMR 29th Annual Meeting
+ VIEW FULL Press Release -
Acceleron Pharma to Present at the 27th Annual Canaccord Adams Global Growth Conference
+ VIEW FULL Press Release -
ACE-011 Improves Multiple Myeloma Bone Disease in a Preclinical Model
+ VIEW FULL Press Release -
Acceleron Pharma’s ACE-031 Increases Muscle Mass and Strength in Preclinical Studies
+ VIEW FULL Press Release -
Acceleron Pharma Appoints James Desiderio, Ph.D. as Vice President, Program Managemen
+ VIEW FULL Press Release -
Acceleron Pharma Appoints Robert Steininger as Senior Vice President, Manufacturing
+ VIEW FULL Press Release -
Acceleron Pharma to Present at the Cowen 27th Annual Health Care Conference
+ VIEW FULL Press Release -
Acceleron Pharma to Present at the Rodman & Renshaw 8th Annual Healthcare Conference
+ VIEW FULL Press Release -
Acceleron Pharma to Present at the MBC’s MASS Opportunities Conference
+ VIEW FULL Press Release -
Acceleron Pharma Presents ACE-011 Preclinical Data Demonstrating Both Anabolic and Anti-Resorptive Properties
+ VIEW FULL Press Release -
Acceleron Pharma to Present ACE-011 Preclinical Data at the Annual Meeting of the American Society for Bone and Mineral Research
+ VIEW FULL Press Release -
Acceleron Pharma Closes $30M Series B Financing
+ VIEW FULL Press Release -
Acceleron Initiates Phase 1 Clinical Trial of ACE-011, a Novel Treatment for Bone Loss
+ VIEW FULL Press Release -
Acceleron Pharma Appoints Matthew L. Sherman, M.D. as Chief Medical Officer
+ VIEW FULL Press Release -
Acceleron Pharma Appoints Glenn Batchelder as CEO and Adds Richard F. Pops to Board of Directors
+ VIEW FULL Press Release -
Acceleron Pharma, Developing Drugs to Treat Musculoskeletal and Metabolic Disorders, Secures $25 Million in Series A Funding
+ VIEW FULL Press Release